The purpose of this study was to evaluate the change of vital signs and adverse reactions with intravenous nonionic iodine contrast media using computed tomography (CT).
Introduction
Contrast-enhanced computed tomography (CT) is one of the most important procedures in the imaging of the oral and maxillofacial regions (1) (2) (3) (4) . However, it is well-known that intravascular administration of contrast medium may cause a severe, sometimes life-threatening adverse reaction (5) (6) (7) (8) (9) (10) (11) (12) . Death has been reported in cases of patients administered nonionic contrast media (5), although they have been shown to be significantly safer than conventional ionic agents (6) . Therefore, emergency equipment must be available whenever an intravenous contrast agent is administered.
In our hospital, we routinely monitor the vital signs of the patients who received contrast-enhanced CT. That is systolic and diastolic arterial blood pressure, pulse rate and saturation of arterial blood oxygen. The purpose of this study was to evaluate the change of vital signs and adverse reactions with intravenous nonionic iodine contrast media using CT.
Materials and Methods
Seventy-six patients (52 males, 24 females; age 26 to 89 years, mean age 57.8 years) who received contrast-enhanced CT with nonionic iodine in our hospital from December 2002 to June 2005 were studied. One nonionic contrast media was used: Iohexol 300 mgI/mL(Omunipaque 300 Syringe, Daiichi Pharmaceutical, Tokyo, Japan).
Intravenous pretesting was routinely performed prior to the examination with 1 mL of contrast medium followed by close observation for at least 5 min. Contrast medium was administered as a bolus injection of 100 mL at a rate of 0. 
Results
Change of vital signs in contrast-enhanced CT was shown in Table 1 3, Ajinomoto, Tokyo, Japan) was administered. After that, pulse rate returned to nearly normal and nausea was disappeared.
Discussion
The adverse reactions to contrast media for intravascular use have been reported by many researchers (5-12).
Katayama et al(5) reported in their large-scale study that the prevalence of all adverse reactions to nonionic contrast media was 3.13% and of severe reactions 0.04%. Yuasa et al (11) showed that the overall incidence of adverse reactions to contrast media was 2.1%. Kurabayashi et al (12) reported that the overall prevalence was 3.7%, and the most common symptom was nausea followed by pharyngeal discomfort.
Our results indicated only one of 76 patients (1.3%) had nausea with rising of pulse rate. The value in our study was not dissimilar.
Katayama et al (5) showed that patients at risk, such as history of adverse drug reactions, asthma and cardiac disease, must be identified before the contrast-enhanced CT, and all possible measures must be taken to deal effectively with spontaneous anaphylactic reactions.
Mikkonen et al (10) indicated that the risk factors for late reactions were allergy, medicine allergy, previous adverse reaction to contrast medium and other diseases including diabetes mellitus, heart-, liver-and kidney diseases. We system (Aquilion 64, Toshiba Medical Systems, Tokyo, Japan). Wienbeck et al (14) reported the frequency and type of intravenous injection site complications associated with high-flow power injection of nonionic contrast medium in MDCT. We consider that the further study of adverse reactions with intravenous nonionic iodine contrast media using MDCT is necessary to compare MDCT with CT.
In conclusion, monitoring vital signs is very useful method for early detection of the accidental adverse reactions.
